Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 359

1.

Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial.

Mosenzon O, Wiviott SD, Cahn A, Rozenberg A, Yanuv I, Goodrich EL, Murphy SA, Heerspink HJL, Zelniker TA, Dwyer JP, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Kato ET, Gause-Nilsson IAM, Fredriksson M, Johansson PA, Langkilde AM, Sabatine MS, Raz I.

Lancet Diabetes Endocrinol. 2019 Jun 10. pii: S2213-8587(19)30180-9. doi: 10.1016/S2213-8587(19)30180-9. [Epub ahead of print]

PMID:
31196815
2.

Response by Mann et al to Letter Regarding Article, "Effects of Liraglutide Versus Placebo on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease: Results From the LEADER Trial".

Mann JFE, Fonseca V, Mosenzon O, Raz I, Goldman B, Idorn T, von Scholten BJ, Poulter NR.

Circulation. 2019 May 28;139(22):e1017-e1018. doi: 10.1161/CIRCULATIONAHA.119.040419. Epub 2019 May 28. No abstract available.

PMID:
31136226
3.

Effect of Injection Site Cooling and Warming on Insulin Glargine Pharmacokinetics and Pharmacodynamics.

Bitton G, Rom V, Hadelsberg U, Raz I, Cengiz E, Weinzimer S, Tamborlane WV.

J Diabetes Sci Technol. 2019 May 8:1932296819842151. doi: 10.1177/1932296819842151. [Epub ahead of print]

PMID:
31067999
4.

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. Reply.

Wiviott SD, Raz I, Sabatine MS.

N Engl J Med. 2019 May 9;380(19):1881-1882. doi: 10.1056/NEJMc1902837. No abstract available.

PMID:
31067395
5.

Effect of Flash Glucose Monitoring Technology on Glycemic Control and Treatment Satisfaction in Patients With Type 2 Diabetes.

Yaron M, Roitman E, Aharon-Hananel G, Landau Z, Ganz T, Yanuv I, Rozenberg A, Karp M, Ish-Shalom M, Singer J, Wainstein J, Raz I.

Diabetes Care. 2019 Jul;42(7):1178-1184. doi: 10.2337/dc18-0166. Epub 2019 Apr 29.

PMID:
31036546
6.

Cardiac and Inflammatory Biomarkers Are Associated with Worsening Renal Outcomes in Patients with Type 2 Diabetes Mellitus: Observations from SAVOR-TIMI 53.

Zelniker TA, Morrow DA, Mosenzon O, Gurmu Y, Im K, Cahn A, Raz I, Steg PG, Leiter LA, Braunwald E, Bhatt DL, Scirica BM.

Clin Chem. 2019 Jun;65(6):781-790. doi: 10.1373/clinchem.2018.298489. Epub 2019 Apr 15.

PMID:
30988169
7.

Dapagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Previous Myocardial Infarction.

Furtado RHM, Bonaca MP, Raz I, Zelniker TA, Mosenzon O, Cahn A, Kuder J, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Ruff CT, Nicolau JC, Gause-Nilsson IAM, Fredriksson M, Langkilde AM, Sabatine MS, Wiviott SD.

Circulation. 2019 May 28;139(22):2516-2527. doi: 10.1161/CIRCULATIONAHA.119.039996. Epub 2019 Mar 18.

PMID:
30882239
8.

Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus.

Kato ET, Silverman MG, Mosenzon O, Zelniker TA, Cahn A, Furtado RHM, Kuder J, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Bonaca MP, Ruff CT, Desai AS, Goto S, Johansson PA, Gause-Nilsson I, Johanson P, Langkilde AM, Raz I, Sabatine MS, Wiviott SD.

Circulation. 2019 May 28;139(22):2528-2536. doi: 10.1161/CIRCULATIONAHA.119.040130. Epub 2019 Mar 18.

PMID:
30882238
9.

An evaluation of the efficacy and safety of Tofogliflozin for the treatment of type II diabetes.

Aharon-Hananel G, Raz I.

Expert Opin Pharmacother. 2019 May;20(7):781-790. doi: 10.1080/14656566.2019.1583210. Epub 2019 Mar 5.

PMID:
30835599
10.

Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus.

Zelniker TA, Wiviott SD, Raz I, Im K, Goodrich EL, Furtado RHM, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Sabatine MS.

Circulation. 2019 Apr 23;139(17):2022-2031. doi: 10.1161/CIRCULATIONAHA.118.038868.

PMID:
30786725
11.

Effects of Liraglutide Versus Placebo on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease.

Mann JFE, Fonseca V, Mosenzon O, Raz I, Goldman B, Idorn T, von Scholten BJ, Poulter NR.

Circulation. 2018 Dec 18;138(25):2908-2918. doi: 10.1161/CIRCULATIONAHA.118.036418.

12.

Patient clusters based on HbA1c trajectories: A step toward individualized medicine in type 2 diabetes.

Karpati T, Leventer-Roberts M, Feldman B, Cohen-Stavi C, Raz I, Balicer R.

PLoS One. 2018 Nov 14;13(11):e0207096. doi: 10.1371/journal.pone.0207096. eCollection 2018.

13.

SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.

Zelniker TA, Wiviott SD, Raz I, Im K, Goodrich EL, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Furtado RHM, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Sabatine MS.

Lancet. 2019 Jan 5;393(10166):31-39. doi: 10.1016/S0140-6736(18)32590-X. Epub 2018 Nov 10.

PMID:
30424892
14.

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.

Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Silverman MG, Zelniker TA, Kuder JF, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Ruff CT, Gause-Nilsson IAM, Fredriksson M, Johansson PA, Langkilde AM, Sabatine MS; DECLARE–TIMI 58 Investigators.

N Engl J Med. 2019 Jan 24;380(4):347-357. doi: 10.1056/NEJMoa1812389. Epub 2018 Nov 10.

PMID:
30415602
15.

Validity of diagnostic codes and estimation of prevalence of diabetic foot ulcers using a large electronic medical record database.

Cahn A, Altaras T, Agami T, Liran O, Touaty CE, Drahy M, Pollack R, Raz I, Chodick G, Zucker I.

Diabetes Metab Res Rev. 2019 Feb;35(2):e3094. doi: 10.1002/dmrr.3094. Epub 2018 Nov 20.

PMID:
30378240
16.

Prevalence and Outcomes of Polyvascular (Coronary, Peripheral, or Cerebrovascular) Disease in Patients With Diabetes Mellitus (From the SAVOR-TIMI 53 Trial).

Gutierrez JA, Scirica BM, Bonaca MP, Steg PG, Mosenzon O, Hirshberg B, Im K, Raz I, Braunwald E, Bhatt DL.

Am J Cardiol. 2019 Jan 1;123(1):145-152. doi: 10.1016/j.amjcard.2018.09.014. Epub 2018 Sep 26.

PMID:
30366601
17.

Petition to replace current OGTT criteria for diagnosing prediabetes with the 1-hour post-load plasma glucose ≥ 155 mg/dl (8.6 mmol/L).

Bergman M, Manco M, Sesti G, Dankner R, Pareek M, Jagannathan R, Chetrit A, Abdul-Ghani M, Buysschaert M, Olsen MH, Nilsson PM, Medina JL, Roth J, Groop L, Del Prato S, Raz I, Ceriello A.

Diabetes Res Clin Pract. 2018 Dec;146:18-33. doi: 10.1016/j.diabres.2018.09.017. Epub 2018 Sep 28. Review.

PMID:
30273707
18.

Comparison of HBA1c Goals Proposed by an Algorithm To Those Set By Different Members of Healthcare Teams Within the Dartmouth Hitchcock Health System.

Delgado-Hurtado JJ, Cahn A, Raz I, Comi RJ.

Endocr Pract. 2018 Aug;24(8):705-709. doi: 10.4158/EP-2018-0102.

PMID:
30183396
19.

Cardiovascular benefit in the limelight: shifting type 2 diabetes treatment paradigm towards early combination therapy in patients with overt cardiovascular disease.

Shehadeh N, Raz I, Nakhleh A.

Cardiovasc Diabetol. 2018 Aug 22;17(1):117. doi: 10.1186/s12933-018-0760-6. No abstract available.

20.

The design and rationale for the Dapagliflozin Effect on Cardiovascular Events (DECLARE)-TIMI 58 Trial.

Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Silverman MG, Bansilal S, Bhatt DL, Leiter LA, McGuire DK, Wilding JP, Gause-Nilsson IA, Langkilde AM, Johansson PA, Sabatine MS.

Am Heart J. 2018 Jun;200:83-89. doi: 10.1016/j.ahj.2018.01.012. Epub 2018 Feb 7.

PMID:
29898853
21.

The Berlin Declaration: A call to improve early actions related to type 2 diabetes. Why is primary care important?

Khunti K, Gavin JR 3rd, Boulton AJM, Blickstead R, McGill M, Ceriello A, Raz I, Sadikot S, Wood DA, Cos X, Kalra S, Das AK, Espinosa López C; Berlin Declaration Steering Group.

Prim Care Diabetes. 2018 Oct;12(5):383-392. doi: 10.1016/j.pcd.2018.04.003. Epub 2018 May 8. Review.

PMID:
29752222
22.

Correction to: Incidence and Risk Factors for Mortality Following Bariatric Surgery: a Nationwide Registry Study.

Sakran N, Sherf-Dagan S, Blumenfeld O, Romano-Zelekha O, Raziel A, Keren D, Raz I, Hershko D, Gralnek IM, Shohat T, Goitein D.

Obes Surg. 2018 Sep;28(9):2670-2671. doi: 10.1007/s11695-018-3274-0.

PMID:
29744715
23.

Incidence and Risk Factors for Mortality Following Bariatric Surgery: a Nationwide Registry Study.

Sakran N, Sherf-Dagan S, Blumenfeld O, Romano-Zelekha O, Raziel A, Keren D, Raz I, Hershko D, Gralnek IM, Shohat T, Goitein D.

Obes Surg. 2018 Sep;28(9):2661-2669. doi: 10.1007/s11695-018-3212-1. Erratum in: Obes Surg. 2018 Apr 25;:.

PMID:
29627947
24.

The Berlin Declaration: A call to action to improve early actions related to type 2 diabetes. How can specialist care help?

Ceriello A, Gavin JR 3rd, Boulton AJM, Blickstead R, McGill M, Raz I, Sadikot S, Wood DA, Cos X, Khunti K, Kalra S, Das AK, López CE; Berlin Declaration Steering Group.

Diabetes Res Clin Pract. 2018 May;139:392-399. doi: 10.1016/j.diabres.2018.03.037. Epub 2018 Mar 27.

PMID:
29596943
25.

Blood pressure and cardiovascular outcomes in patients with diabetes and high cardiovascular risk.

Bergmark BA, Scirica BM, Steg PG, Fanola CL, Gurmu Y, Mosenzon O, Cahn A, Raz I, Bhatt DL; SAVOR-TIMI 53 Investigators.

Eur Heart J. 2018 Jun 21;39(24):2255-2262. doi: 10.1093/eurheartj/ehx809.

26.

DECLARE-TIMI 58: Participants' baseline characteristics.

Raz I, Mosenzon O, Bonaca MP, Cahn A, Kato ET, Silverman MG, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Gause-Nilsson IAM, Langkilde AM, Johansson PA, Sabatine MS, Wiviott SD.

Diabetes Obes Metab. 2018 May;20(5):1102-1110. doi: 10.1111/dom.13217. Epub 2018 Feb 14.

PMID:
29322605
27.

Calculating individualized glycaemic targets using an algorithm based on expert worldwide diabetologists: Implications in real-life clinical practice.

Alvarez-Guisasola F, Cebrián-Cuenca AM, Cos X, Ruiz-Quintero M, Millaruelo JM, Cahn A, Raz I, Orozco-Beltrán D; Spanish Society of Family Medicine Diabetes Group.

Diabetes Metab Res Rev. 2018 Mar;34(3). doi: 10.1002/dmrr.2976. Epub 2018 Jan 24.

PMID:
29271560
28.

Cardiovascular Outcomes Trials in Type 2 Diabetes: Where Do We Go From Here? Reflections From a Diabetes Care Editors' Expert Forum.

Cefalu WT, Kaul S, Gerstein HC, Holman RR, Zinman B, Skyler JS, Green JB, Buse JB, Inzucchi SE, Leiter LA, Raz I, Rosenstock J, Riddle MC.

Diabetes Care. 2018 Jan;41(1):14-31. doi: 10.2337/dci17-0057.

29.

Omega-loop gastric bypass is more effective for weight loss but negatively impacts liver enzymes: a registry-based comprehensive first-year analysis.

Spivak H, Munz Y, Rubin M, Raz I, Shohat T, Blumenfeld O.

Surg Obes Relat Dis. 2018 Feb;14(2):175-180. doi: 10.1016/j.soard.2017.11.006. Epub 2017 Nov 9.

PMID:
29217131
30.

Cardiovascular Outcomes According to Urinary Albumin and Kidney Disease in Patients With Type 2 Diabetes at High Cardiovascular Risk: Observations From the SAVOR-TIMI 53 Trial.

Scirica BM, Mosenzon O, Bhatt DL, Udell JA, Steg PG, McGuire DK, Im K, Kanevsky E, Stahre C, Sjöstrand M, Raz I, Braunwald E.

JAMA Cardiol. 2018 Feb 1;3(2):155-163. doi: 10.1001/jamacardio.2017.4228.

PMID:
29214305
31.

Risk Assessment in Patients With Diabetes With the TIMI Risk Score for Atherothrombotic Disease.

Bergmark BA, Bhatt DL, Braunwald E, Morrow DA, Steg PG, Gurmu Y, Cahn A, Mosenzon O, Raz I, Bohula E, Scirica BM.

Diabetes Care. 2018 Mar;41(3):577-585. doi: 10.2337/dc17-1736. Epub 2017 Dec 1.

32.

Digital health technology and diabetes management.

Cahn A, Akirov A, Raz I.

J Diabetes. 2018 Jan;10(1):10-17. doi: 10.1111/1753-0407.12606. Epub 2017 Nov 6. Review.

PMID:
28872765
33.

Influences of Breakfast on Clock Gene Expression and Postprandial Glycemia in Healthy Individuals and Individuals With Diabetes: A Randomized Clinical Trial.

Jakubowicz D, Wainstein J, Landau Z, Raz I, Ahren B, Chapnik N, Ganz T, Menaged M, Barnea M, Bar-Dayan Y, Froy O.

Diabetes Care. 2017 Nov;40(11):1573-1579. doi: 10.2337/dc16-2753. Epub 2017 Aug 22.

PMID:
28830875
34.

Immigration to Israel during childhood is associated with diabetes at adolescence: a study of 2.7 million adolescents.

Peled A, Gordon B, Twig G, Mendlovic J, Derazne E, Lisnyansky M, Raz I, Afek A.

Diabetologia. 2017 Nov;60(11):2226-2230. doi: 10.1007/s00125-017-4399-8. Epub 2017 Aug 19.

PMID:
28821907
35.

Health-related quality-of-life implications of cardiovascular events in individuals with type 2 diabetes mellitus: A subanalysis from the Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus (SAVOR)-TIMI 53 trial.

Briggs AH, Bhatt DL, Scirica BM, Raz I, Johnston KM, Szabo SM, Bergenheim K, Mukherjee J, Hirshberg B, Mosenzon O.

Diabetes Res Clin Pract. 2017 Aug;130:24-33. doi: 10.1016/j.diabres.2016.12.019. Epub 2017 Jan 23.

36.

Different effects of bariatric surgical procedures on dyslipidemia: a registry-based analysis.

Spivak H, Sakran N, Dicker D, Rubin M, Raz I, Shohat T, Blumenfeld O.

Surg Obes Relat Dis. 2017 Jul;13(7):1189-1194. doi: 10.1016/j.soard.2017.03.013. Epub 2017 Mar 23.

PMID:
28456511
37.

Oral Administration of β-Glucosylceramide for the Treatment of Insulin Resistance and Nonalcoholic Steatohepatitis: Results of a Double-Blind, Placebo-Controlled Trial.

Lalazar G, Zigmond E, Weksler-Zangen S, Ya'acov AB, Levy MS, Hemed N, Raz I, Ilan Y.

J Med Food. 2017 May;20(5):458-464. doi: 10.1089/jmf.2016.3753. Epub 2017 Apr 7.

PMID:
28387617
38.

Pharmacological management of nonalcoholic fatty liver disease in type 2 diabetes.

Cernea S, Cahn A, Raz I.

Expert Rev Clin Pharmacol. 2017 May;10(5):535-547. doi: 10.1080/17512433.2017.1300059. Epub 2017 Mar 6. Review.

PMID:
28276774
39.

Hypoglycaemia manifestations and recurrent events: Lessons from the SAVOR-TIMI 53 outcome study.

Cahn A, Mosenzon O, Bhatt DL, Leibowitz G, Yanuv I, Rozenberg A, Iqbal N, Hirshberg B, Stahre C, Im K, Kanevsky E, Raz I.

Diabetes Obes Metab. 2017 Jul;19(7):1045-1050. doi: 10.1111/dom.12903. Epub 2017 Mar 8.

PMID:
28181728
40.

Response to Comment on Cefalu et al. Update and Next Steps for Real-World Translation of Interventions for Type 2 Diabetes Prevention: Reflections From a Diabetes Care Editors' Expert Forum. Diabetes Care 2016;39:1186-1201.

Cefalu WT, Buse JB, Tuomilehto J, Fleming GA, Ferrannini E, Gerstein HC, Bennett PH, Ramachandran A, Raz I, Rosenstock J, Kahn SE.

Diabetes Care. 2017 Feb;40(2):e23-e24. doi: 10.2337/dci16-0036. No abstract available.

41.

Continuous subcutaneous insulin infusion-an opportunity for better care but not a "magic pill".

Cahn A, Roitman E, Aharon-Hananel G, Raz I.

Endocrine. 2017 Apr;56(1):4-6. doi: 10.1007/s12020-016-1217-x. Epub 2016 Dec 30. No abstract available.

PMID:
28039560
42.
43.

An update on DPP-4 inhibitors in the management of type 2 diabetes.

Cahn A, Cernea S, Raz I.

Expert Opin Emerg Drugs. 2016 Dec;21(4):409-419. Epub 2016 Nov 18. Review.

PMID:
27809608
44.

Improvement in Glucose Control in Difficult-to-Control Patients With Diabetes Using a Novel Flash Glucose Monitoring Device.

Ish-Shalom M, Wainstein J, Raz I, Mosenzon O.

J Diabetes Sci Technol. 2016 Nov 1;10(6):1412-1413. Print 2016 Nov. No abstract available.

45.

Effect of Saxagliptin on Renal Outcomes in the SAVOR-TIMI 53 Trial.

Mosenzon O, Leibowitz G, Bhatt DL, Cahn A, Hirshberg B, Wei C, Im K, Rozenberg A, Yanuv I, Stahre C, Ray KK, Iqbal N, Braunwald E, Scirica BM, Raz I.

Diabetes Care. 2017 Jan;40(1):69-76. doi: 10.2337/dc16-0621. Epub 2016 Oct 17.

46.

Upregulation of Mitochondrial Content in Cytochrome c Oxidase Deficient Fibroblasts.

Kogot-Levin A, Saada A, Leibowitz G, Soiferman D, Douiev L, Raz I, Weksler-Zangen S.

PLoS One. 2016 Oct 25;11(10):e0165417. doi: 10.1371/journal.pone.0165417. eCollection 2016.

47.

Prognostic Implications of Biomarker Assessments in Patients With Type 2 Diabetes at High Cardiovascular Risk: A Secondary Analysis of a Randomized Clinical Trial.

Scirica BM, Bhatt DL, Braunwald E, Raz I, Cavender MA, Im K, Mosenzon O, Udell JA, Hirshberg B, Pollack PS, Steg PG, Jarolim P, Morrow DA.

JAMA Cardiol. 2016 Dec 1;1(9):989-998. doi: 10.1001/jamacardio.2016.3030.

PMID:
27681000
48.

Combined Analysis of Three Large Interventional Trials With Gliptins Indicates Increased Incidence of Acute Pancreatitis in Patients With Type 2 Diabetes.

Tkáč I, Raz I.

Diabetes Care. 2017 Feb;40(2):284-286. doi: 10.2337/dc15-1707. Epub 2016 Sep 22. Review.

PMID:
27659407
49.

Update and Next Steps for Real-World Translation of Interventions for Type 2 Diabetes Prevention: Reflections From a Diabetes Care Editors' Expert Forum.

Cefalu WT, Buse JB, Tuomilehto J, Fleming GA, Ferrannini E, Gerstein HC, Bennett PH, Ramachandran A, Raz I, Rosenstock J, Kahn SE.

Diabetes Care. 2016 Jul;39(7):1186-201. doi: 10.2337/dc16-0873. Epub 2016 Jun 9. Review.

50.

Improved Insulin Pharmacokinetics Using a Novel Microneedle Device for Intradermal Delivery in Patients with Type 2 Diabetes.

Kochba E, Levin Y, Raz I, Cahn A.

Diabetes Technol Ther. 2016 Sep;18(9):525-31. doi: 10.1089/dia.2016.0156. Epub 2016 Aug 8.

Supplemental Content

Support Center